mRNA COVID-19 vaccine study for stem cell transplant patients
Part of Blood & lymphatic, Cancer, Infections clinical trials.
This trial tests a new self-amplifying mRNA COVID-19 vaccine (LUNAR-COV19) compared to the standard Pfizer vaccine (Comirnaty) in adults who have had a stem cell transplant. The goal is to see if the new vaccine works better and is safe for transplant recipients.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You had a stem cell transplant from a donor within the last 365 days
- Your cancer has not come back or gotten worse since the transplant
- You have not had a COVID-19 infection in the last 28 days
- You are not taking high doses of steroids (more than 1 mg per kg per day) in the last week
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a vaccine designed to boost immunity against CMV (a common virus) and prevent active CMV infection in people receiving a half-matched stem cell transplant. It may help protect you from CMV-related complications after transplant.
This study tests a new type of COVID-19 vaccine that is designed to train your immune system to make stronger, longer-lasting protection. You may be able to join if you are 40–64, have already had at least two doses of a mRNA COVID-19 vaccine (Pfizer or Moderna) more than 4 months ago, and are generally healthy.
This trial studies a vaccine designed to help the body fight cytomegalovirus (CMV) in children who test positive for CMV and are about to receive a donor stem cell transplant. If it works, it may reduce CMV-related illness during recovery after transplant.
This Phase 1 trial tests a donated immune-cell treatment (T cells) to help immunocompromised people fight or resist COVID-19 after they recently received a bone marrow or stem cell transplant. It aims to see if the treatment is safe and if it helps the body respond better to the virus.
This trial is for people with high-risk acute lymphoblastic leukemia who are getting a stem cell transplant from a family donor. After transplant, you'd receive a treatment that combines specially designed immune cells (CAR T cells) that target your leukemia, plus a vaccine that helps those cells work better.
This trial tests whether giving a CMV vaccine to stem cell donors can help protect recipients from CMV infection after transplant. It is for adults with specific blood cancers who are CMV-positive and have a matched related donor.
Hear when a new Hematopoietic and Lymphatic System Neoplasm trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.